Abstract | BACKGROUND: OBJECTIVE: METHODS: In this double-blind, parallel-group phase I trial (ClinicalTrials.gov identifier NCT03247673), healthy adult males were randomized (1:1:1) to receive a single dose of CT-P16 5 mg/kg, EU- bevacizumab 5 mg/kg, or US- bevacizumab 5 mg/kg. Primary study endpoints were area under the concentration-time curve (AUC) from time zero to infinity (AUC∞), AUC from time zero to the last quantifiable concentration (AUClast), and maximum serum concentration (Cmax). Pharmacokinetic equivalence was shown if the 90% confidence intervals (CIs) of the geometric mean (GM) ratios of the AUC∞, AUClast, and Cmax were within the predefined bioequivalence margin of 80-125%. Safety and immunogenicity were also evaluated. RESULTS: A total of 144 subjects were randomized: 47 to CT-P16, 49 to EU- bevacizumab, and 48 to US- bevacizumab. The 90% CIs for the GM ratios of AUC∞, AUClast, and Cmax for CT-P16/EU- bevacizumab, CT-P16/US- bevacizumab, and EU- bevacizumab/US- bevacizumab comparisons were all within the bioequivalence margin. Mean serum concentration-time profiles, secondary pharmacokinetic parameters, and safety and immunogenicity profiles were comparable across all three treatment groups. CONCLUSION: CLINICAL TRIALS REGISTRATION: NCT03247673.
|
Authors | Sang-Heon Cho, Seunghoon Han, Jong-Lyul Ghim, Moon-Suk Nam, Sunyoung Yu, Taehong Park, Sinhye Kim, Jihun Bae, Jae-Gook Shin |
Journal | BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
(BioDrugs)
Vol. 33
Issue 2
Pg. 173-181
(Apr 2019)
ISSN: 1179-190X [Electronic] New Zealand |
PMID | 30850957
(Publication Type: Clinical Trial, Phase I, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Antibodies, Monoclonal
- Biosimilar Pharmaceuticals
- Bevacizumab
|
Topics |
- Adult
- Antibodies, Monoclonal
(adverse effects, blood, pharmacokinetics)
- Bevacizumab
(adverse effects, blood, pharmacokinetics)
- Biosimilar Pharmaceuticals
(adverse effects, blood, pharmacokinetics)
- Double-Blind Method
- Healthy Volunteers
- Humans
- Male
- Middle Aged
- Therapeutic Equivalency
- Young Adult
|